Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.43 |
| ▸ | BPTF | Q12830 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL20510794 | 0.87 | CHRNA7 (0.48) | CHRNB2CHRNA4CHRNA7ROCK2ROCK1 | |
| SCHEMBL13355121 | 0.81 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA7ROCK2ROCK1 | |
| SCHEMBL13322710 | 0.80 | ROCK2 (0.49) | CHRNB2CHRNA4CHRNA7ROCK2ROCK1 | |
| SCHEMBL10111971 | 0.76 | BPTF (0.56) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL14704620 | 0.76 | BPTF (0.56) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL1631742 | 0.75 | ADRB1 (0.58) | CHRNB2CHRNA4 | |
| SCHEMBL30040793 | 0.75 | ADRB1 (0.58) | CHRNB2CHRNA4 | |
| SCHEMBL28962419 | 0.72 | BPTF (0.66) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL15102773 | 0.72 | BPTF (0.66) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL25584599 | 0.72 | MAPT (0.47) | ROCK2ROCK1CDC42BPBTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-11-21 | — | — | US | disclosed |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-25 | — | — | US | disclosed |
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961249-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | CHRNB2 48/4885CHRNA4 168/4885CHRNA7 161/4885 |
| US-20200039985-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | CHRNB2 35/4885CHRNA4 153/4885CHRNA7 148/4885 |
| US-20210363145-A1 | NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | CHRNB2 35/4885CHRNA4 153/4885CHRNA7 148/4885 |
| US-11820774-B2 | Modulators of the sigma-2 receptor and their method of use | SIGMAR1, TMEM97, OPRM1 | CHRNB2 48/4885CHRNA4 168/4885CHRNA7 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.